Case Report
Korean J Hematol 2007; 42(2):
Published online June 30, 2007
https://doi.org/10.5045/kjh.2007.42.2.176
© The Korean Society of Hematology
골수형성이상증후군 환자에서 발생한 아자시티딘 연관 간독성 1예
김진수, 임주한, 이현규, 박현민, 이문희, 김철수
인하대학교병원 혈액종양내과,
서울대학교병원 혈액종양내과
Azacitidine-induced Hepatotoxicity in a Patient with Myelodysplastic Syndrome
Hematopoietic stem cell transplantation remains the only curative option for myelodysplastic syndrome (MDS), but the prevalence of the disease in elderly people limits broad application of the procedure, particularly in lower risk group. Azacitidine has been recently approved by the U.S. Food and Drug Administration for MDS regardless of subtype on French-American-British classification. Adverse effects of azacitidine include gastrointestinal, hematological and infusion-related reactions. Azacitidine induced hepatotoxicity has been reported mainly in patients with previous hepatobiliary disease, e.g., extensive tumor infiltration in liver, liver cirrhosis and cholelithiasis. We report here a case of azacitidine-induced hepatitis under no predisposition to hepatobiliary disease.
Keywords Myelodysplastic syndrome, Azacitidine, Adverse effects, Hepatitis, Toxic, Hepatitis, Drug-induced
PDF
Standard view
Export citation
Share Article
Case Report
Korean J Hematol 2007; 42(2): 176-179
Published online June 30, 2007 https://doi.org/10.5045/kjh.2007.42.2.176
Copyright © The Korean Society of Hematology.
골수형성이상증후군 환자에서 발생한 아자시티딘 연관 간독성 1예
김진수, 임주한, 이현규, 박현민, 이문희, 김철수
인하대학교병원 혈액종양내과,
서울대학교병원 혈액종양내과
Azacitidine-induced Hepatotoxicity in a Patient with Myelodysplastic Syndrome
Jin Soo Kim, Joo Han Lim, Hyeon Gyu Yi, Hyun min Park, Moon Hee Lee, Chul Soo Kim
Division of Hematology, Oncology, Departments of Medicine, Inha University Hospital, Incheon
Seoul National University Hospital, Seoul, Korea
Abstract
Hematopoietic stem cell transplantation remains the only curative option for myelodysplastic syndrome (MDS), but the prevalence of the disease in elderly people limits broad application of the procedure, particularly in lower risk group. Azacitidine has been recently approved by the U.S. Food and Drug Administration for MDS regardless of subtype on French-American-British classification. Adverse effects of azacitidine include gastrointestinal, hematological and infusion-related reactions. Azacitidine induced hepatotoxicity has been reported mainly in patients with previous hepatobiliary disease, e.g., extensive tumor infiltration in liver, liver cirrhosis and cholelithiasis. We report here a case of azacitidine-induced hepatitis under no predisposition to hepatobiliary disease.
Keywords: Myelodysplastic syndrome, Azacitidine, Adverse effects, Hepatitis, Toxic, Hepatitis, Drug-induced
Previous Article
Article Tools
Stats or Metrics
Share this article on
Related articles in BR
-
Monosomal and complex karyotypes as prognostic parameters in patients with International Prognostic Scoring System higher risk myelodysplastic syndrome treated with azacitidine
Kyung-Lim Hwang, Moo-Kon Song, Ho-Jin Shin, Hae-Jung Na, Dong-Hun Shin, Joong-Keun Kim, Joon-Ho Moon, Jae-Sook Ahn, Ik-Chan Song, Junshik Hong, Gyeong-won Lee, and Joo-Seop Chung
Blood Res 2014; 49(4): 234-240 -
Lenalidomide for anemia correction in lower-risk del(5q) myelodysplastic syndrome patients of Asian ethnicity
Junshik Hong, Yoo Jin Lee, Sung Hwa Bae, Jun Ho Yi, Sungwoo Park, Myung Hee Chang, Young Hoon Park, Shin Young Hyun, Joo-Seop Chung, Ji Eun Jang, Joo Young Jung, So-Yeon Jeon, Seo-Young Song, Hawk Kim, Dae Sik Kim, Sung-Hyun Kim, Min Kyoung Kim, Sang Hoon Han, Seonyang Park, Yoo-Jin Kim, Je-Hwan Lee, on behalf of the AML/MDS Working Party of the Korean Society of Hematology
Blood Res 2021; 56(2): 102-108 -
Myelodysplastic syndrome with genetic predisposition
Meerim Park
Blood Res 2021; 56(S1): S34-S38
